2 terminated. 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 2 | Terminated 2 |
Follow CKD: new trials by email Literature Review of CKD trials Research Report on CKD
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| ARTEMIS: Ravulizumab to Protect Patients With CKD From CSA-AKI and MAKE Placebo, Ravulizumab - Chronic Kidney Disease, CKD | Phase 3 | Terminated | Alexion Pharmaceuticals, Inc. | 555 | 2023-04-06 | 2026-10-29 |
| Effect of Subcutaneous Semaglutide on Kidney Transplant Candidacy Semaglutide 2 mg/1.5 ml (1.34 mg/ml), prefilled pen-injector for subcutaneous injection solution, Placebo 1.5 ml, prefilled pen-injector for subcutaneous injection solution - CKD, Diabetic Kidney Disease | Phase 3 | Terminated | Geisinger Clinic | 15 | 2021-07-23 | 2024-02-09 |
Renal Insufficiency, Chronic (2) · Diabetic Nephropathies (1) · Heart Diseases (1) · Obesity (1) · Obesity, Morbid (1)
Chronic Disease (2) · Disease Attributes (2) · Female Urogenital Diseases (2) · Female Urogenital Diseases and Pregnancy Complications (2) · Kidney Diseases (2) · Male Urogenital Diseases (2) · Pathologic Processes (2) · Pathological Conditions, Signs and Symptoms (2) · Renal Insufficiency (2) · Urogenital Diseases (2) · Urologic Diseases (2) · Body Weight (1) · Cardiovascular Diseases (1) · Diabetes Complications (1) · Diabetes Mellitus (1)
ravulizumab (1) · semaglutide (1)
Alexion Pharmaceuticals, Inc. (1) · Geisinger Clinic (1)
United States (2) · Argentina (1) · Australia (1) · Brazil (1) · Canada (1) · China (1) · France (1) · Germany (1) · Hong Kong (1) · India (1) · Israel (1) · Italy (1) · Japan (1) · Netherlands (1) · Poland (1)
Alex R Chang, MD, MS (1) · Tolga Baykal, MD, PhD (1)